Search

Your search keyword '"Pham-Thi, Nhân"' showing total 183 results

Search Constraints

Start Over You searched for: Author "Pham-Thi, Nhân" Remove constraint Author: "Pham-Thi, Nhân"
183 results on '"Pham-Thi, Nhân"'

Search Results

1. MASK-air: An OECD (Organisation for Economic Co-operation and Development) Best Practice for Public Health on Integrated Care for Chronic Diseases

2. PR-CIM: a Variation-Aware Binary-Neural-Network Framework for Process-Resilient Computation-in-memory

3. Poor Rhinitis and Asthma Control Is Associated With Decreased Health-Related Quality of Life and Utilities: A MASK-air Study

5. Impairment of EQ-5D-5L Domains According to Allergic Rhinitis and Asthma Control: A MASK-air Real-World Study

6. Development and validation of an electronic daily control score for asthma (e-DASTHMA): a real-world direct patient data study

7. Cutoff Values of MASK-air Patient-Reported Outcome Measures

8. Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants

9. Academic Productivity of Young People With Allergic Rhinitis: A MASK-air Study

10. The Allergic Rhinitis and Its Impact on Asthma (ARIA) Approach of Value-Added Medicines: As-Needed Treatment in Allergic Rhinitis

13. Poor rhinitis and asthma control is associated with decreased health-related quality-of-life and utilities: A MASK-air study

14. MASK-air®: An OECD (Organisation for Economic Coordination and Development) Best Practice for Public Health on integrated care for chronic diseases.

15. Relevance of individual bronchial symptoms for asthma diagnosis and control in patients with rhinitis:A MASK-air study

16. Relevance of individual bronchial symptoms for asthma diagnosis and control in patients with rhinitis: A MASK‐air study.

17. Proof‐of‐concept study of anti‐Fel d 1 IgY antibodies in cat food using the MASK‐air® app.

18. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence

19. Mobile Technology in Allergic Rhinitis: Evolution in Management or Revolution in Health and Care?

21. Patient‐centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA‐EAACI approach – ARIA‐EAACI Task Force Report

22. Improvement of daily allergy control by sublingual immunotherapy: A MASK ‐air® study

23. Digitally-enabled, patient-centred care in rhinitis and asthma multimorbidity: The ARIA-MASK-air approach.

24. Consistent trajectories of rhinitis control and treatment in 16,177 weeks : the MASK-air® longitudinal study

25. Patient-centered digital biomarkers for allergic respiratory diseases and asthma:The ARIA-EAACI approach – ARIA-EAACI Task Force Report

26. Patient‐centred digital biomarkers for allergic respiratory diseases and asthma: the ARIA‐EAACI approach

27. Digitally‐enabled, patient‐centred care in rhinitis and asthma multimorbidity: The ARIA‐MASK‐air ® approach

28. Development and validation of an electronic daily control score for asthma (e-DASTHMA):a real-world direct patient data study

29. Frey Syndrome

31. Consistent trajectories of rhinitis control and treatment in 16,177 weeks

32. Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases

33. MASK‐air ® real‐world data in respiratory allergy in old‐age adults

34. Digitally‐enabled, patient‐centred care in rhinitis and asthma multimorbidity: The ARIA‐MASK‐air ® approach

35. Cutoff Values of MASK-air Patient-Reported Outcome Measures

36. Consistent trajectories of rhinitis control and treatment in 16,177 weeks: The MASK‐air® longitudinal study

37. Real‐world data using mHealth apps in rhinitis, rhinosinusitis and their multimorbidities

38. The ARIA-MASK-air® approach

39. The ARIA approach of Value-Added Medicines:as-needed treatment in allergic rhinitis

41. A study using MASK-air® real-world data

43. Comparison of rhinitis treatments using MASK ‐air® data and considering the minimal important difference

45. Results of a Bayesian mixed-effects model

46. Comparison of rhinitis treatments using MASK-air® data and considering the minimal important difference

47. Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK-air real-world data.

48. Development and validation of combined symptom-medication scores for allergic rhinitis*

49. Consistent trajectories of rhinitis control and treatment in 16,177 weeks: The MASK-air® longitudinal study.

50. Comparison of rhinitis treatments using MASK-air® data and considering the minimal important difference.

Catalog

Books, media, physical & digital resources